These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 10543335)

  • 41. Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective.
    O'Brien BJ; Goeree R; Bernard L; Rosner A; Williamson T
    Clin Ther; 2001 Dec; 23(12):2038-49. PubMed ID: 11813937
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
    Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H
    Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate.
    Chancellor MB; Appell RA; Sathyan G; Gupta SK
    Clin Ther; 2001 May; 23(5):753-60. PubMed ID: 11394733
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder.
    Leung HY; Yip SK; Cheon C; Liu YS; Lau J; Wong HK; Chung KH
    BJU Int; 2002 Sep; 90(4):375-80. PubMed ID: 12175392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence.
    Reinberg Y; Crocker J; Wolpert J; Vandersteen D
    J Urol; 2003 Jan; 169(1):317-9. PubMed ID: 12478180
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is extended-release oxybutynin (Ditropan XL) or tolterodine (Detrol) more effective in the treatment of an overactive bladder?
    Hartnett NM; Saver BG
    J Fam Pract; 2001 Jul; 50(7):571. PubMed ID: 11485700
    [No Abstract]   [Full Text] [Related]  

  • 48. Prominent complaint: a guide to medical therapy of overactive bladder syndrome in older women.
    Jafarabadi M; Ghanbari Z; Hashemi S; Nemati M; Haghollahi F; Azimi Nekoo E
    Acta Med Iran; 2015; 53(2):125-8. PubMed ID: 25725183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder.
    Getsios D; Caro JJ; Ishak KJ; El-Hadi W; Payne K
    Clin Ther; 2004 Mar; 26(3):431-8. PubMed ID: 15110136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?
    Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M
    Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current pharmacotherapeutic strategies for overactive bladder.
    Garely AD; Burrows LJ
    Expert Opin Pharmacother; 2002 Jul; 3(7):827-33. PubMed ID: 12083983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence.
    Dmochowski RR; Sand PK; Zinner NR; Gittelman MC; Davila GW; Sanders SW;
    Urology; 2003 Aug; 62(2):237-42. PubMed ID: 12893326
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine.
    Appell RA; Abrams P; Drutz HP; Van Kerrebroeck PE; Millard R; Wein A
    World J Urol; 2001 Apr; 19(2):141-7. PubMed ID: 11374317
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder.
    Kreder K; Mayne C; Jonas U
    Eur Urol; 2002 Jun; 41(6):588-95. PubMed ID: 12074774
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Muscarinic receptor antagonists in the treatment of overactive bladder.
    Chapple CR
    Urology; 2000 May; 55(5A Suppl):33-46; discussion 50. PubMed ID: 10767450
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
    Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
    J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of overactive bladder: the Antimuscarinic Clinical Effectiveness Trial.
    Appell RA
    Curr Urol Rep; 2002 Oct; 3(5):343-4. PubMed ID: 12354340
    [No Abstract]   [Full Text] [Related]  

  • 60. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
    Chapple CR; Rechberger T; Al-Shukri S; Meffan P; Everaert K; Huang M; Ridder A;
    BJU Int; 2004 Feb; 93(3):303-10. PubMed ID: 14764127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.